Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05529953
Other study ID # PID2019-107837RB-100
Secondary ID PID2019-107837RB
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2021
Est. completion date July 15, 2021

Study information

Verified date October 2022
Source Spanish National Research Council
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The oral bioavailability of Oleanolic acid (OA) when formulated as functional olive oil, and its mechanisms of systemic transport, will be approached by mean of randomized and controlled trial with 20 healthy volunteers. Ten individuals randomly selected will receive 55 mL of the functional OA-enriched olive oil (equivalent dose 30 mg OA) as part of an experimental breakfast. The other ten participants will receive within this experimental meal the same amount of the control olive oil. Immediately before and after eating the respective breakfasts, aliquots of cubital blood will be drawn every hour, over a postprandial period of 7 hours. Since in this trial design, each participant is his/her own control, a four-week washout period is established, after which a new series of tests that cross the type of olive oil consumed will be carried out. From the aliquots of cubital blood, sera will be obtained by centrifugation. The extraction and quantification of serum OA will be realized by gas chromatography (GC) using flame ionization (FID) and mass spectrometry (MS) detectors. In the pharmacokinetic analysis of data, a mono-compartmental model will be assumed. It will be determined: 1) absorption parameters such as the maximum concentration achieved and the timing for it, the constant of absorption and the area under the curve; 2) distribution parameters such as the constant and volume of distribution; 3) metabolism parameters, such as the OA fraction associated with albumin; and 4) elimination parameters such as the elimination constant, the half-life and the clearance. To demonstrate the presence of OA in postprandial TRL, chylomicron and VLDL fractions will be prepared by plasma ultrafiltration in normal saline, and hydrolysed with pancreatic enzyme. The possible presence of OA among the TRL-derived lipids will be evaluated. The content of apo B48 and B100, as markers of the presence of chylomicrons and VLDL, respectively, will be determined by ELISA. Other parameters related to glycemic control, such as serum insulin, C-peptide and GLP-1 will be analyzed by ELISA.


Description:

Design and implementation of the biovailability assays The study of oral bioavailability of Oleanolic acid (OA) when formulated as functional olive oil, and its mechanisms of systemic transport, will be approached by mean of a postprandial intervention with 20 healthy volunteers. The participants will be recruited after the complete biochemical and hematological analysis yield results within normal limits, and after checking in their electronic medical histories that they do not suffer from digestive, metabolic or oncologic disorders or any other pathology that, in opinion of the clinical investigators, could prevent them from participating in the trial. For their inclusion in the trial, it is also required that they grant the written consent to the protocols approved by the Institutional Committees for Human Research, after being conveniently informed both orally and documentally. The fieldwork will be performed in the Day Hospital of the Endocrinology and Nutrition Service of the University Hospitals 'Virgen del Rocio' from Seville (SPAIN). Sample size. The main quantitative variable to be examined in this trial is OA serum concentration. In the absence of consistent baseline data published so far, data from the analysis of OA in sera of the PREDIABOLE Study (ISRCTN03372660) have been used. A cohort of 25 participants from the control group, consuming commercial olive oil, was selected, and an average baseline concentration of 155 ± 72 ng OA/mL was determined. Considering this, it is now postulated that the plasma OA content will increase by at least 50% as consequence of the intake of the functional olive oil (equivalent dose 30 mg OA). To prove this unilateral hypothesis test, with a confidence level of 90% (risk α=0.01, zα=1.645) and a power of 95% (zβ=1.645), a sample size of at least 17 volunteers is required. Assuming that losses lower than 15% are tolerable, the adjusted sample size would be 20 subjects. Anamnesis and physical examination of participants. The anamnesis will include vital data and general history collecting all the symptoms that the individual may present, their medical and surgical history, as well as pharmacological treatments followed. Information about lifestyle, perception of the own body image, diet and kind and intensity of physical activity will be also obtained. In addition, the muscle mass, fatty compartment (adipose panniculus), existence of edema, etc. will be examined. Likewise, systolic and diastolic blood pressure and heart rate will be determined. Anthropometric study and body composition. The anthropometric study will include the determination of total body weight, height, body mass index (BMI), as well as waist and hip circumferences. The study and evaluation of these variables will be carried out in accordance with the guidelines of the International Society for the Advancement of kinanthropometry (ISAK). The study of body composition will be carried out by electrical bioimpedance, using a TANITA® body composition analyzer model BC-418MA. Fat mass, lean mass, muscle mass, total water, bone mass, basal metabolism and visceral fat will be quantified with this technique, making use of prediction equations validated and adjusted by age and sex. Biochemical studies. Samples of fasting cubital blood will be drawn to determine the parameters of general, hepatic and renal biochemistry. In addition, a complete urine analysis will be performed, which include the habitual physical, chemical and microscopically measurements. These determinations will be carried out at the Laboratory of Analysis and Clinical Biochemistry of 'Virgen del Rocío' University Hospitals of Seville. Intervention The participants will be encouraged to avoid the consumption of alcoholic beverages and tobacco during the day preceding the execution of the assays. On trial days, and after 12 hours of overnight fasting, blood samples will be drawn from the cubital vein. Subsequently, ten individuals randomly selected will receive 55 mL of the functional OA-enriched olive oil (equivalent dose 30 mg OA) as part of an experimental breakfast, that includes coffee, skimmed milk and whole-grain toast. The other ten participants will receive within the experimental meal the same amount of the control olive oil. After eating the respective breakfasts, aliquots of cubital blood will be drawn every hour, over a postprandial period of 7 hours. During this time, free access to water intake will be allowed. A four-week washout period is established, after which a new series of tests that cross the type of olive oil consumed will be carried out. Pharmacokinetic study of OA From the aliquots of cubital blood, sera will be obtained by centrifugation, and NaN3, PMSF and aprotinin will be added as preservatives, to avoid their proteolytic degradation. Serum samples will be stored at -80 0C in the laboratories of the IG-CSIC until analysis. The extraction and fractionation of serum OA will be realized by liquid/liquid and solid phase extractions, whereas the identification and quantification of the triterpene will be completed by GC-FID and GC-MS. In the pharmacokinetic analysis of data, a mono-compartmental model will be assumed. From data of the serum contents of free OA throughout the postprandial period the following parameters will be determined: 1) absorption parameters such as the maximum concentration achieved and the timing for it, the constant of absorption and the area under the curve; 2) distribution parameters such as the constant and volume of distribution; 3) metabolism parameters, such as the OA fraction associated with albumin; and 4) elimination parameters such as the elimination constant, the half-life and the clearance. For calculations, the SigmaPLot pharmacokinetic analysis module (Systat Software Inc., San Jose, CA, USA) will be used. Study of the presence of OA in triglyceride rich lipoproteins (TRL). Chylomicrons will be first isolated from plasma in normal saline by centrifugation at 100,000 × g for 20 min. Very low density lipoproteins (VLDL) will be subsequently separated at 230,000 × g for 18 h. The chylomicron and VLDL fractions will be hydrolyzed with pancreatic enzyme. The released lipids will be extracted with chloroform:methanol (2:1), and fractionated by solid/liquid extraction with methanol:chloroform (1:1) and isopropanol:acetonitrile:water (2:1:1). The free fatty acids (FFA) composition will be analysed by GC-FID as the correspondent methyl esters. The possible presence of OA among the TRL-derived lipids will be evaluated after fractionation and GC-MS analysis. The content of apo B48 and B100, as markers of the presence of chylomicrons and VLDL, respectively, will be determined by ELISA. Other biochemical parameters serum insulin, C-peptide and GLP-1 will be analyzed by ELISA.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date July 15, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - healthy women and men - aged 18-30 years - BMI in the range 18.5-29.9 kg/m2 - complete biochemical and hematological analysis yield results within normal limits - grant the written consent to the protocols approved by the Institutional Committees for Human Research of the CSIC and HUVR, after being conveniently informed both orally and documentally. Exclusion Criteria: - suffering from digestive, metabolic or oncologic disorders or any other pathology that, in opinion of the clinical investigators, could prevent them from participating in the trial (checked in their electronic medical histories).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)
Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects
Control commercial olive oil
Postprandial study of Oleanolic acid bioavailability in healthy subjects

Locations

Country Name City State
Spain Universitary Hospitals Virgen del Rocío Seville Sevilla

Sponsors (3)

Lead Sponsor Collaborator
Spanish National Research Council Andalusian Health Service, Universidad Pablo de Olavide

Country where clinical trial is conducted

Spain, 

References & Publications (8)

Castellano JM, Guinda A, Delgado T, Rada M, Cayuela JA. Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes. Diabetes. 2013 Jun;62(6):1791-9. doi: 10.2337/db12-1215. Review. — View Citation

Castellano JM, Ramos-Romero S, Perona JS. Oleanolic Acid: Extraction, Characterization and Biological Activity. Nutrients. 2022 Jan 31;14(3). pii: 623. doi: 10.3390/nu14030623. Review. — View Citation

Fernández-Aparicio Á, Correa-Rodríguez M, Castellano JM, Schmidt-RioValle J, Perona JS, González-Jiménez E. Potential Molecular Targets of Oleanolic Acid in Insulin Resistance and Underlying Oxidative Stress: A Systematic Review. Antioxidants (Basel). 2022 Aug 3;11(8). pii: 1517. doi: 10.3390/antiox11081517. Review. — View Citation

Guinda A, Rada M, Delgado T, Gutiérrez-Adánez P, Castellano JM. Pentacyclic triterpenoids from olive fruit and leaf. J Agric Food Chem. 2010 Sep 8;58(17):9685-91. doi: 10.1021/jf102039t. — View Citation

Jiménez-Sánchez A, Martínez-Ortega AJ, Remón-Ruiz PJ, Piñar-Gutiérrez A, Pereira-Cunill JL, García-Luna PP. Therapeutic Properties and Use of Extra Virgin Olive Oil in Clinical Nutrition: A Narrative Review and Literature Update. Nutrients. 2022 Mar 31;14(7). pii: 1440. doi: 10.3390/nu14071440. Review. — View Citation

Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA, Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 1993 Jan 4;98(1):33-49. — View Citation

Rada M, Castellano JM, Perona JS, Guinda Á. GC-FID determination and pharmacokinetic studies of oleanolic acid in human serum. Biomed Chromatogr. 2015 Nov;29(11):1687-92. doi: 10.1002/bmc.3480. Epub 2015 May 5. — View Citation

Santos-Lozano JM, Rada M, Lapetra J, Guinda Á, Jiménez-Rodríguez MC, Cayuela JA, Ángel-Lugo A, Vilches-Arenas Á, Gómez-Martín AM, Ortega-Calvo M, Castellano JM. Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trial. Diabetes Obes Metab. 2019 Nov;21(11):2526-2534. doi: 10.1111/dom.13838. Epub 2019 Aug 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Plasma Concentration Versus Time Curve (AUC) of Oleanolic acid Quantification of the Oleanolic acid plasma concentration every 60 minutes postpradial 6-hours period
Primary Identification and quantification of the Oleanolic acid presence in triglyceride-rich lipoproteins isolation and analysis of Oleanolic acid in postprandial chylomicrons and VLDL postpradial 6-hours period
Secondary Fraction of the Oleanolic acid associated to serum albumin Spectrophotometric analysis of the Oleanolic acid-serum albumin complexes postpradial 6-hours period
Secondary Influence of the Oleanolic acid-based intervention on the postprandial glycemic control Determination of glycaemia, insulin, C-peptide and GLP-1 postpradial 6-hours period
Secondary Influence of the Oleanolic acid-based intervention on plasma lipids Determination of circulating triglycerides, total cholesterol, LDL, HDL postpradial 6-hours period
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1